In a transvaginal tru-cut biopsy, guided by ultrasound, a needle is inserted through the vaginal wall into a pelvic lesion and a few pieces of tissue are obtained for examination.
This clinical trial is organized to evaluate the safety and efficacy of transvaginal tru-cut biopsy in a large group of patients with tumors in the small pelvis.

开始日期2021-05-01

申办/合作机构

First Faculty of Medicine, Charles University in Prague

EUCTR2016-000971-26-CZ / Not yet recruiting临床4期

Liposoms (drug delivery systems) in kinetically guided therapy of ovarian platinum-resistant carcinoma with doxorubicin using plasmafiltration - Kinetically therapy of ovarian platinum-resistant carcinoma with doxorubicin using plasmafiltration

开始日期2016-04-04

申办/合作机构

First Faculty of Medicine, Charles University in Prague

EUCTR2007-002893-76-CZ / Unknown statusN/A

MEtabolic Therapy with Trimetazidine in Acute heart failure: an open pilot randomized trial (The METTA – PRAGUE 10 Trial) - METTA - PRAGUE 10

开始日期2008-02-13

申办/合作机构

First Faculty of Medicine, Charles University in Prague

100 项与 First Faculty of Medicine, Charles University in Prague 相关的临床结果

登录后查看更多信息

0 项与 First Faculty of Medicine, Charles University in Prague 相关的专利（医药）

登录后查看更多信息

2,598

项与 First Faculty of Medicine, Charles University in Prague 相关的文献（医药）

2024-07-01·Redox Biology

Deciphering pathophysiological mechanisms underlying cystathionine beta-synthase-deficient homocystinuria using targeted metabolomics, liver proteomics, sphingolipidomics and analysis of mitochondrial function

Article

作者: Olsen, Thomas ; Majtan, Tomas ; Sokolova, Jitka ; Ditrói, Tamás ; Hansikova, Hana ; Kruger, Warren D ; Nagy, Péter ; Kožich, Viktor ; Křížková, Michaela ; Vit, Ondrej ; Krijt, Jakub ; Ida, Tomoaki ; Akaike, Takaaki ; Kuchař, Ladislav ; Petrak, Jiri

BACKGROUNDCystathionine β-synthase (CBS)-deficient homocystinuria (HCU) is an inherited disorder of sulfur amino acid metabolism with varying severity and organ complications, and a limited knowledge about underlying pathophysiological processes. Here we aimed at getting an in-depth insight into disease mechanisms using a transgenic mouse model of HCU (I278T).METHODSWe assessed metabolic, proteomic and sphingolipidomic changes, and mitochondrial function in tissues and body fluids of I278T mice and WT controls. Furthermore, we evaluated the efficacy of methionine-restricted diet (MRD) in I278T mice.RESULTSIn WT mice, we observed a distinct tissue/body fluid compartmentalization of metabolites with up to six-orders of magnitude differences in concentrations among various organs. The I278T mice exhibited the anticipated metabolic imbalance with signs of an increased production of hydrogen sulfide and disturbed persulfidation of free aminothiols. HCU resulted in a significant dysregulation of liver proteome affecting biological oxidations, conjugation of compounds, and metabolism of amino acids, vitamins, cofactors and lipids. Liver sphingolipidomics indicated upregulation of the pro-proliferative sphingosine-1-phosphate signaling pathway. Liver mitochondrial function of HCU mice did not seem to be impaired compared to controls. MRD in I278T mice improved metabolic balance in all tissues and substantially reduced dysregulation of liver proteome.CONCLUSIONThe study highlights distinct tissue compartmentalization of sulfur-related metabolites in normal mice, extensive metabolome, proteome and sphingolipidome disruptions in I278T mice, and the efficacy of MRD to alleviate some of the HCU-related biochemical abnormalities.

2024-07-01·Neurocirugía (English Edition)

Pediatric atlas anatomy and its implications for fracture treatment: an anatomical and radiological study

Article

作者: Salavcová, Lucie ; Rybárová, Michaela ; Naňka, Ondřej ; Geri, Gábor ; Štulík, Vojtěch ; Štulík, Jan

INTRODUCTION AND OBJECTIVESThe objective of the study was: (1) to describe changes in the shape of the atlas during growth, including gender and side differences; (2) to assess the dimension essential for identification of the optimal entry point; (3) to determine the age limit for a safe insertion of 3.5-mm screws into the lateral masses according to our own limiting parameters.MATERIALS AND METHODSDimensions of the atlas were measured on 200 CT scans of the craniocervical junction in individuals aged 0-18 years and on 34 anatomical specimens of the first cervical vertebra (aged 2.5-18 years). Both series were divided according to the gender and age. The values measured on CT scans were used for statistical comparison of data in boys and girls and comparison of the right and left sides.RESULTSThe atlas reaches its maximum growth rate between 0 and 2 years of age, then the growth decelerates and continues until the age of 18 years. The proportion of dimensions of C1 vertebral foramens changes with age. The youngest children show a relatively greater distance from the left to the right medial pedicle; around the age of 5 the values get even and subsequently the distance from the inner wall of anterior to posterior arch gets relatively greater. The transverse foramen has a slightly oval shape throughout the period of growth. Statistically significant differences between boys and girls were observed primarily between 12 and 18 years of age.CONCLUSIONThe study has proved adequate size of lateral masses for insertion of 3.5-mm screws in all patients from the age of 5 years. In younger children, the patient´s anatomy should be respected and the surgical technique tailored accordingly.

2024-06-10·Biomedical Papers

Utility of fine-needle aspiration biopsy (FNAB) in parotid pleomorphic adenoma diagnosis and management

Article

作者: Novak, Stepan ; Balko, Jan ; Kuchar, Martin ; Fikova, Alzbeta ; Plzak, Jan ; Kalfert, David ; Zabrodsky, Michal ; Dostalova, Lucie

PURPOSEPleomorphic adenoma (PA), the most common benign tumour of the parotid gland, requires accurate preoperative diagnosis owing to its capacity for malignant transformation. The aim of this study was to evaluate our experience with ultrasound-guided fine-needle aspiration biopsy (FNAB) in the diagnostic algorithm for patients with PA and to assess clinical outcomes for those with different surgical approaches.MATERIAL AND METHODSWe carried out a retrospective analysis of patients treated for parotid gland mass between 2010 and 2016. These had had preoperative FNAB and had undergone subsequent surgery.RESULTS165 patients had FNAB with the result of PA and the definitive histology confirmed PA in 159 cases (96.4%). On the other hand, in 179 patients, the definitive histology showed PA and the preoperative FNAB result corresponded in 159 cases (88.9%). The measured sensitivity, specificity and accuracy of ultrasound-guided FNAB in the diagnosis of PA were, respectively, 88.83%, 96.23% and 92.31%. Most of the patients underwent superficial or partial superficial parotidectomy, followed by extracapsular dissection which was associated with statistically lower risk of facial nerve injury (P=0.04).CONCLUSIONUltrasound-guided FNAB is simple, accurate and valuable in the diagnosis of PA and provides results that can lead to the choice of less invasive operative treatment.

项与 First Faculty of Medicine, Charles University in Prague 相关的新闻（医药）

2024-06-13

·PRNewswire

Protalix BioTherapeutics to Host In-Person Investor Day to Discuss Current Treatment Landscapes and Clinical Results for Fabry Disease and Uncontrolled Gout

Event will take place on Wednesday, June 26, 2024 in New York CARMIEL, Israel, June 13, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell based protein expression system, today announced that it will host an in-person investor day at the Lotte Palace New York Hotel in New York on Wednesday, June 26, 2024 at 8:30 a.m. Eastern Daylight Time (EDT). The investor day will feature presentations by the following key opinion leaders: Aleš Linhart, DSc, FESC (Charles University, Prague), who will discuss the treatment landscape for Fabry disease and perspectives on Elfabrio® (pegunigalsidase alfa), a plant cell-expressed PEGylated recombinant α-Galactosidase-A enzyme approved for adult patients with Fabry disease. Naomi Schlesinger, MD (University of Utah), who will discuss the current treatment landscape for uncontrolled gout and top-line results from the First-in-Human Phase I single ascending dose clinical trial of PRX-115, a plant cell-expressed recombinant PEGylated uricase. In addition, the event will include a corporate overview and strategy presentation by Dror Bashan, Protalix's President and Chief Executive Officer. A live question and answer session will follow the formal presentations. To register for the event, please click here. About Aleš Linhart, DSc, FESC Aleš Linhart, DSc, FESC is currently heading the Department of Cardiovascular Medicine of the First Medical Faculty and General University in Prague, Czech Republic and serves as vice-dean for international affairs of the First Faculty of Medicine of Charles University in Prague. He obtained his MD degree at Charles University in Prague, received his training in cardiology and vascular medicine at General University Hospital in Prague and Broussais Hospital in Paris, France. In 2004 he was appointed professor at Charles University in Prague. His research focuses mainly on Fabry disease, metabolic cardiomyopathies, noninvasive cardiac imaging, and atherosclerosis. He is member of several scientific societies, namely Czech and European Society of Cardiology (ESC). He served as the chairman of the Working Group on Myocardial and Pericardial Diseases of the ESC and is the immediate past president of the Czech Society of Cardiology. He authored or co-authored more than 450 scientific peer-reviewed papers, 85 book chapters, and three monographs. About Naomi Schlesinger, MD Naomi Schlesinger, MD is the Harold J, Ardella T, and Helen T Stevenson Presidential Endowed Chair of Rheumatology, Professor and Chief Division of Rheumatology, Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, UT. She is a previous Chief of the Division of Rheumatology at Rutgers-Robert Wood Johnson Medical School and Director of Rutgers Robert Wood Johnson Medical School Gout Center. Dr. Schlesinger is a previous President of the NJ Rheumatology Association and current President of the Utah Rheumatology Association and was the recipient of the 2015 Rheumatologist of The Year award by the Arthritis Foundation - NJ Chapter. Dr. Schlesinger is a noted authority in the field of gout, having published many papers regarding the diagnosis, treatment, and better understanding of the pathogenesis of gout. Dr. Schlesinger's research has won recognition, including the work titled: Efficacy of canakinumab (ACZ885), a fully human anti-Interleukin (IL)-1beta monoclonal antibody, in the prevention of flares in gout patients initiating allopurinol therapy, which was selected as one of the five highest-ranking abstracts that will likely shape our treatment paradigms for years to come in the 2010 ACR/ ARHP Annual Scientific Meeting and the work titled: Erectile dysfunction is common among gout patients, which was selected (one of 13) for inclusion in the official 2014 EULAR Press Conference from over 4000 abstracts. Other pioneering work includes the treatment of gout flares with topical ice, seasonality of gout, diagnosing gout using ultrasound, understanding the pathogenesis of bone erosions in gout, and the importance of anti-inflammatory treatment in gout. Dr. Schlesinger serves as the American College of Rheumatology (ACR) abstract Co-Chair on metabolic and crystal arthropathies, a member of the ACR Global Engagement Special Committee (GESC), and a member of the ACR Annual Meeting Planning Committee (AMPC). She is a Co-Director of the International Gout and Hyperuricemia Center, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. She serves as a consultant to pharmaceutical companies in the field of gout. About Protalix BioTherapeutics, Inc. Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. It is the first company to gain U.S. Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. This unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights to taliglucerase alfa for the treatment of Gaucher disease, Protalix's first product manufactured through ProCellEx, excluding in Brazil, where Protalix retains full rights. Protalix's second product, Elfabrio®, was approved by both the FDA and the European Medicines Agency in May 2023. Protalix has partnered with Chiesi Farmaceutici S.p.A. for the global development and commercialization of Elfabrio. Protalix's development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: PRX-115, a plant cell-expressed recombinant PEGylated uricase for the treatment of uncontrolled gout; PRX-119, a plant cell-expressed long action DNase I for the treatment of NETs-related diseases; and others. Investor Contact Mike Moyer, Managing Director LifeSci Advisors 617 308 4306 [email protected] Logo: SOURCE Protalix BioTherapeutics, Inc.

临床1期上市批准

100 项与 First Faculty of Medicine, Charles University in Prague 相关的药物交易

登录后查看更多信息

100 项与 First Faculty of Medicine, Charles University in Prague 相关的转化医学

登录后查看更多信息